Abstract
Mesenchymal stem cells (MSCs) are multipotent progenitors that have the abilities of selfrenewal and multiple direction differentiation. The osteogenic potential of MSCs holds great promise for bone defect repair and bone disease treatment. For a long time studies about osteogenic differentiation of MSCs have emphasized on the effect of extrinsic regulators and the corresponding transcription factors controlling cell fate. In fact, cell fate is determined by lineage specific gene expression that is regulated more specifically by epigenetic mechanism. Over the last decade, some progress has been made in epigenetic researches of MSCs osteogenic differentiation. DNA methylation, histone modifications and microRNA (miRNA) are all verified important mechanisms regulating MSCs differentiation. Epigenetic regulation might provide novel treatment targets for promoting bone formation. In this review, we will summarize the recent advance about the epigenetic mechanism that control MSCs commitment to osteoblasts and the potential clinical application of MSCs epigenetics in future.
Keywords: DNA methylation, epigenetic, histone modification, mesenchymal stem cells, microRNA, osteogenic differentiation.
Current Stem Cell Research & Therapy
Title:Epigenetic Regulation of Osteogenic Differentiation of Mesenchymal Stem Cells
Volume: 11 Issue: 3
Author(s): Gang Fu, Aishu Ren, Yu Qiu and Yi Zhang
Affiliation:
Keywords: DNA methylation, epigenetic, histone modification, mesenchymal stem cells, microRNA, osteogenic differentiation.
Abstract: Mesenchymal stem cells (MSCs) are multipotent progenitors that have the abilities of selfrenewal and multiple direction differentiation. The osteogenic potential of MSCs holds great promise for bone defect repair and bone disease treatment. For a long time studies about osteogenic differentiation of MSCs have emphasized on the effect of extrinsic regulators and the corresponding transcription factors controlling cell fate. In fact, cell fate is determined by lineage specific gene expression that is regulated more specifically by epigenetic mechanism. Over the last decade, some progress has been made in epigenetic researches of MSCs osteogenic differentiation. DNA methylation, histone modifications and microRNA (miRNA) are all verified important mechanisms regulating MSCs differentiation. Epigenetic regulation might provide novel treatment targets for promoting bone formation. In this review, we will summarize the recent advance about the epigenetic mechanism that control MSCs commitment to osteoblasts and the potential clinical application of MSCs epigenetics in future.
Export Options
About this article
Cite this article as:
Fu Gang, Ren Aishu, Qiu Yu and Zhang Yi, Epigenetic Regulation of Osteogenic Differentiation of Mesenchymal Stem Cells, Current Stem Cell Research & Therapy 2016; 11 (3) . https://dx.doi.org/10.2174/1574888X10666150528153313
DOI https://dx.doi.org/10.2174/1574888X10666150528153313 |
Print ISSN 1574-888X |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3946 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Molecular Mechanisms of Inflammation. Anti-Inflammatory Benefits of Virgin Olive Oil and the Phenolic Compound Oleocanthal
Current Pharmaceutical Design Alzheimer’s Disease And Type 2 Diabetes: Exploring The Association To Obesity And Tyrosine Hydroxylase
CNS & Neurological Disorders - Drug Targets Mutations of mtDNA in some Vascular and Metabolic Diseases
Current Pharmaceutical Design Assessment and Relevance of Carotid Intima-Media Thickness (C-IMT) in Primary and Secondary Cardiovascular Prevention
Current Pharmaceutical Design Novel Therapeutic Strategy in the Management of COPD: A Systems Medicine Approach
Current Medicinal Chemistry Phenolic Compounds as Nutraceuticals or Functional Food Ingredients
Current Pharmaceutical Design Hypoxia-Inducible Factors and Sphingosine 1-Phosphate Signaling
Anti-Cancer Agents in Medicinal Chemistry Neuropeptide Y Induces Cardiomyocyte Hypertrophy <i>via</i> Attenuating miR-29a-3p in Neonatal Rat Cardiomyocytes
Protein & Peptide Letters Clinical Aspects and Therapeutic Perspectives of Relaxin
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Antioxidant Properties of Hydroxycinnamic Acids: A Review of Structure- Activity Relationships
Current Medicinal Chemistry Advanced Glycation End Products (AGEs) and Cardiovascular Disease (CVD) in Diabetes
Cardiovascular & Hematological Agents in Medicinal Chemistry Gene-Gene and Gene-Clinical Factors Interaction in Acute Myocardial Infarction: A New Detailed Risk Chart
Current Pharmaceutical Design Pharmacology and Clinical Potential of Direct Thrombin Inhibitors
Current Pharmaceutical Design Therapeutic Use of Antioxidants in Sepsis
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery (Discontinued) Structure-to-function Relationship of Carbohydrates in the Mechanism of Lysosomal Storage Disorders (LSDs)
Current Organic Chemistry Blood-Brain Barrier Integrity and Glial Support: Mechanisms that can be Targeted for Novel Therapeutic Approaches in Stroke
Current Pharmaceutical Design “Endothelial Progenitor Cells” as a Therapeutic Strategy in Cardiovascular Disease
Current Vascular Pharmacology Non-Alcoholic Fatty Liver Disease and Vascular Disease
Current Vascular Pharmacology Stage B: What is the Evidence for Treatment of Asymptomatic Left Ventricular Dysfunction?
Current Cardiology Reviews Is the Vascular System a Main Target for Thyroid Hormones? From Molecular and Biochemical Findings to Clinical Perspectives
Current Vascular Pharmacology